Prostate Cancer Clinical Trial
Official title:
A Phase II Trial of Prostate Stereotactic Radiotherapy
A single arm phase II study of SBRT for prostate cancer to primarily assess acute and late toxicity and secondarily PSA outcomes and quality of life measurements of an extreme hypofractionated regimen of 36.25Gy in 5 fractions over 10-11 days.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | December 2021 |
Est. primary completion date | December 2018 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: - Histologically confirmed diagnosis of adenocarcinoma of the prostate - History/physical examination with digital rectal examination of the prostate within 60 days prior to registration - Histological evaluation of prostate biopsy with assignment of a Gleason score to the biopsy material; Gleason scores 2-7 - Clinical stage T1-2b (DRE) (AJCC 7th edition) within 90 days of registration - PSA < 20 ng/mL within 60 days prior to registration. PSA should not be obtained within 10 days after prostate biopsy. (Every effort should be made to obtain all serum PSA values obtained in the 1 year prior to treatment to allow for calculation of PSA kinetics.) - Not more than one intermediate risk factor (T2b/GS7/PSA 10-20) - Zubrod Performance Status 0-1 within 60 days prior to registration - Age = 21 - Patient must be able to provide study-specific informed consent prior to study entry. - Willingness and ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire Exclusion Criteria: - Prior or concurrent invasive malignancy (except non-melanomatous skin cancer) or lymphomatous/hematogenous malignancy unless continually disease free for a minimum of 5 years. (For example, carcinoma of the oral cavity is permissible; however, patients with prior history of bladder cancer are not allowed) - T-stage = T2c on staging MRI - Evidence of distant metastases - Regional lymph node involvement - Previous radical surgery (prostatectomy), cryosurgery, or HIFU for prostate cancer - Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy - Previous hormonal therapy, such as LHRH agonists (e.g., goserelin, leuprolide) or LHRH antagonists (e.g., degarelix), anti-androgens (e.g., flutamide, bicalutamide), estrogens (e.g., DES), or surgical castration (orchiectomy) - Use of finasteride within 30 days prior to registration. PSA should not be obtained prior to 30 days after stopping finasteride. - Use of dutasteride within 90 days prior to registration. PSA should not be obtained prior to 90 days after stopping dutasteride. - Previous or concurrent cytotoxic chemotherapy for prostate cancer - Severe, active co-morbidity, defined as follows: - Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months - Transmural myocardial infarction within the last 6 months - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration - Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration - Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol. (Patients on Coumadin or other blood thinning agents are eligible for this study.) - Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. Protocol-specific requirements may also exclude immuno-compromised patients. |
Country | Name | City | State |
---|---|---|---|
Singapore | National Cancer Centre Singapore | Singapore |
Lead Sponsor | Collaborator |
---|---|
National Cancer Centre, Singapore |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The rate of late severe GI and GU toxicities | 2 years | ||
Secondary | The rate of late severe GI and GU toxicities | 1 and 5 years | ||
Secondary | The rate of acute severe GI and GU toxicities | 1, 2 and 5 years | ||
Secondary | PSA failure-free survival | 1, 2 and 5 years | ||
Secondary | Disease-free survival (DFS) | 1, 2 and 5 years | ||
Secondary | Time to local progression | 1, 2 and 5 years | ||
Secondary | Time to distant and/or regional failure | 1, 2 and 5 years | ||
Secondary | Disease-specific survival | 1, 2 and 5 years | ||
Secondary | Freedom from biochemical recurrence (FFBR) | 1, 2 and 5 years | ||
Secondary | Overall survival (OS) | 1, 2 and 5 years | ||
Secondary | The change in quality of life outcomes from baseline | 1, 2 and 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |